CytomX

CTMX NASDAQ
11.85
+0.06
+0.51%
After Hours: 11.85 0 0.00% 17:04 07/16 EDT
Open
11.80
Prev Close
11.79
High
12.20
Low
11.65
Volume
326.63K
Avg Vol (3M)
389.36K
52 Week High
27.20
52 Week Low
8.94
% Turnover
0.72%
Market Cap
536.94M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers CytomX CTMX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
MORE >

Recently

Name
Price
%Change